Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label
This article was originally published in The Pink Sheet Daily
Executive Summary
The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.
You may also be interested in...
GSK Drawn To Archemix’s Table By Aptamers For (Another) Option Deal
Package of seven potential anti-inflammatory drugs includes interleukin-23 inhibitor program.
GSK Drawn To Archemix’s Table By Aptamers For (Another) Option Deal
Package of seven potential anti-inflammatory drugs includes interleukin-23 inhibitor program.
Genentech’s Lucentis Ships June 30 Following Approval
Ranibizumab, for the treatment of wet age-related macular degeneration, will be priced at a substantial premium to Pfizer/OSI's Macugen.